Please select the option that best describes you:
Topics:
Gynecologic Oncology • Medical Oncology
Does the PFS and OS data presented at EMSO 2025 for ENGOT-ov65/KEYNOTE-B96 (pembrolizumab + paclitaxel +/- bevacizumab) influence how you will incorporate IO therapy into platinum-resistant ovarian cancer?
If approved, how will you choose between IO therapy and targeted therapy?